secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0000950170-23-069392
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences: FDA requires long-term safety data; NDA filing likely delayed
--------------------------------------------------------------------------------

- FDA supports NDA on two Phase 3 trials but demands long-term safety data beyond 12 weeks for chronic-use label.
- Company expects further FDA input in Q1 2024; NDA submission timing may be delayed.
- Long-term safety data may be collected from cumulative treatment and vaping cessation program.
- Single drug candidate cytisinicline at risk; delay could impact regulatory timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017023069392/0000950170-23-069392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017023069392/achv-20231211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-069392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer